12:00 AM
 | 
May 19, 2003
 |  BioCentury  |  Emerging Company Profile

Dynogen: Let the bladder beware

As anyone who has cared for an elderly parent knows, an aging population means an increasing number of patients will suffer from disorders such as urinary incontinence. The few existing drugs include ditropan, which has been on the market for about 40 years, and Detrol tolteridine. But both are anticholinergics, which can have side effects such as dry mouth, constipation, the inability to sweat and an increase in residual urine.

Dynogen Pharmaceuticals Inc. is focused on changing all that. CSO Karl Thor is a pharmacologist who has spent his entire career in neurourology - the relationship between the urological system and the CNS. After a stint at the NIH, he spent eight years at Eli Lilly and Co. (LLY, Indianapolis, Ind.), where he discovered that duloxetine, a serotonin-norepinephrine reuptake inhibitor, was useful for urinary incontinence.

The drug, Cymbalta duloxetine, has received...

Read the full 712 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >